Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PathoGenesis Tobi Use Per Patient Can Be Raised About 50%, CEO Says

Executive Summary

PathoGenesis believes that per patient use of Tobi inhaled tobramycin can be increased by about 50%.

You may also be interested in...



Chiron Acquiring PathoGenesis For Six Times Consensus 2001 Revenues

Chiron will pay about 6.1 times PathoGenesis' consensus 2001 revenues when it acquires the company for approximately $700 mil. cash.

Chiron Acquiring PathoGenesis For Six Times Consensus 2001 Revenues

Chiron will pay about 6.1 times PathoGenesis' consensus 2001 revenues when it acquires the company for approximately $700 mil. cash.

Sankyo Parke Davis Will Double Sales Force To Market GelTex Cholestagel

Sankyo Parke Davis intends to double its sales force to support the marketing and sales of GelTex' cholesterol reduction agent Cholestagel (colesevelam).

Related Content

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel